Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 2 minute read Pharma Industry News X4 Pharmaceuticals completes merger with Arsanis to advance rare disease and cancer treatments X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases… bypharmanewsdailyMarch 13, 2019